Filing Flows › Comparisons › STLN vs AIRS
Starling Oncology vs Airsculpt Technologies: STLN and AIRS compared
Starling Oncology is the larger company: $170M of revenue in its latest quarter (Q3 2026) against $31.9M for Airsculpt Technologies (Q3 2026). Starling Oncology is growing faster (+24% against -9% a year earlier). Starling Oncology is more profitable, with an operating margin of -1.8% against -13.0%.
Where the money goes: STLN and AIRS
Starling Oncology (STLN) · Q3 2026
Starling Oncology, Q3 2026: revenue $170M (+24% year over year), operating margin -1.8%, net loss $15.7M, operating cash flow $10.1M. The chart follows the revenue to costs, profit and cash.
Airsculpt Technologies (AIRS) · Q3 2026
Airsculpt Technologies, Q3 2026: revenue $31.9M (-9% year over year), operating margin -13.0%, net loss $7.2M, operating cash flow −$3.5M. The chart follows the revenue to costs, profit and cash.
| Starling Oncology (STLN) | Airsculpt Technologies (AIRS) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $170M | $31.9M |
| Revenue growth, Y/Y | +24% | -9% |
| Operating margin | -1.8% | -13.0% |
| Net earnings | −$15.7M | −$7.2M |
| Net margin | -9.3% | -22.5% |
| Operating cash flow | $10.1M | −$3.5M |
| Free cash flow | $8.9M | — |
Where the revenue comes from
Starling Oncology
- Specialty Pharmacy: $109M (64%)
- Patient services: $60.0M (35%)
Questions
Which is bigger, Starling Oncology or Airsculpt Technologies?
Starling Oncology is the larger company: $170M of revenue in its latest quarter (Q3 2026) against $31.9M for Airsculpt Technologies (Q3 2026).
Is Starling Oncology or Airsculpt Technologies growing faster?
Starling Oncology is growing faster (+24% against -9% a year earlier).
Which is more profitable, Starling Oncology or Airsculpt Technologies?
Starling Oncology is more profitable, with an operating margin of -1.8% against -13.0%.
More: Starling Oncology earnings · how Starling Oncology makes money · Airsculpt Technologies earnings · how Airsculpt Technologies makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 6, 2026; 10-Q filed Nov 6, 2026). Fiscal quarters can end on different dates. Not investment advice.